What is the clinical significance of a sigmoid-shaped interventricular septum?

Clinical Significance of Sigmoid Interventricular Septum

In most elderly patients with hypertension, a sigmoid-shaped interventricular septum (isolated basal septal hypertrophy) is a benign age-related finding that does not increase cardiovascular mortality or require treatment, and should not be diagnosed as hypertrophic cardiomyopathy unless there is severe hypertrophy (>18mm), genetic evidence, or other HCM features. 1, 2

Key Diagnostic Distinction

The sigmoid septum represents a common diagnostic conundrum that requires careful differentiation from true hypertrophic cardiomyopathy (HCM):

Benign Sigmoid Septum Characteristics:

• Isolated basal septal hypertrophy confined to the ventricular outflow region
• Strongly associated with age and hypertension 2
• Wall thickness typically ≤18mm 1
• Represents the site where hypertensive LV hypertrophy begins due to greatest regional wall stress 2
• Manifestation of adverse ventricular-arterial coupling 2
• No increased cardiovascular mortality at 15 years in the Framingham Heart Study (3,562 subjects) after adjusting for risk factors 2
• Causative genetic mutations rarely found 2

True HCM Features (requiring different management):

• Wall thickness >18mm (hypertension rarely causes this degree of hypertrophy) 1
• Asymmetric rather than isolated basal hypertrophy 1
• Hypertrophy out of proportion to hypertension severity 1
• Presence of pathogenic genetic variants 1
• Family history of HCM 1
• More advanced diastolic dysfunction 1

Clinical Scenarios Requiring Intervention

While most sigmoid septa are benign, symptomatic left ventricular outflow tract obstruction (LVOTO) can occur in hypercontractile states:

When Sigmoid Septum Becomes Pathologic:

• Dynamic LVOTO with pressure gradients during stress (Valsalva, dobutamine, exercise) 3, 4, 5
• Systolic anterior motion (SAM) of the mitral valve 3, 4, 5
• Symptoms: angina, syncope, exertional dyspnea 3, 4, 5, 6
• Peak gradients can exceed 90-120 mmHg during provocation 4, 5, 6

Treatment Options for Symptomatic Cases:

1. First-line medical therapy: Beta-blockers (metoprolol) or negative inotropes (cibenzoline, disopyramide) 6
2. Percutaneous transluminal septal myocardial ablation (PTSMA) for drug-refractory symptoms 3, 4
3. Endocardial radiofrequency ablation - emerging option with documented success 3

Diagnostic Pitfalls to Avoid

Critical mistake: Diagnosing elderly hypertensive patients with isolated basal septal hypertrophy as having HCM leads to:

• Unnecessary genetic testing and family screening
• Inappropriate activity restrictions
• Unwarranted ICD consideration
• Patient anxiety and insurance implications

The 2024 Canadian guidelines explicitly warn that "isolated basal septal hypertrophy (sigmoid septum) in the elderly individual with hypertension is a common conundrum and the distinction between a benign or pathologic condition might not be clear" 1

Practical Diagnostic Algorithm

Step 1: Measure wall thickness

• <15mm: Not HCM (unless genetic variant + family history)
• 15-18mm: Gray zone - assess other features
• >18mm: Favor HCM over hypertensive heart disease 1

Step 2: Assess hypertrophy pattern

• Isolated basal septum only: Favor benign sigmoid septum
• Asymmetric or diffuse: Favor HCM 1

Step 3: Evaluate clinical context

• Severe hypertension + mild symmetric hypertrophy: Favor hypertensive heart disease
• Mild hypertension + severe/asymmetric hypertrophy: Favor HCM 1

Step 4: Assess for dynamic obstruction

• Perform Valsalva maneuver or dobutamine stress echo if symptoms present 4, 5
• Look for SAM and provocable gradients 4, 5

Step 5: Consider cardiac MRI if uncertain

• Helps differentiate through fibrosis patterns and precise wall thickness measurements 7
• HCM shows different fibrosis location than sigmoid septum 7

Management Recommendations

For asymptomatic sigmoid septum with no LVOTO:

• No specific treatment required 2
• Manage hypertension appropriately
• No activity restrictions
• No genetic testing indicated 1

For symptomatic sigmoid septum with LVOTO:

• Trial of beta-blockers or negative inotropes first 6
• Consider septal reduction therapy (ablation or myectomy) if drug-refractory 3, 4
• Avoid diuretics in acute settings as they can worsen LVOTO 5

The key takeaway: sigmoid septum is typically a benign age-related finding in hypertensive patients that should not be conflated with HCM, though rare symptomatic cases with dynamic obstruction may require intervention.